Education and Training
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which chemotherapy regimen combined with radiation therapy and/or surgery is more effective in treating Ewing's sarcoma or primitive neuroectodermal tumor.
PURPOSE: Randomized phase III trial to compare the effectiveness of different chemotherapy regimens combined with radiation therapy and/or surgery in treating patients who have Ewing's sarcoma or primitive neuroectodermal tumor.
Stanford is currently not accepting patients for this trial.
Intervention(s):
- biological: filgrastim
- drug: cyclophosphamide
- drug: doxorubicin hydrochloride
- drug: etoposide
- drug: ifosfamide
- drug: vincristine sulfate
- procedure: adjuvant therapy
- procedure: conventional surgery
- procedure: neoadjuvant therapy
- radiation: brachytherapy
- radiation: radiation therapy
Eligibility
DISEASE CHARACTERISTICS:
- Histologically confirmed localized Ewing's sarcoma or peripheral primitive
neuroectodermal tumor (PNET) of the bone or soft tissues
- Diagnostic biopsy of primary tumor within 30 days of study
- Paraspinal or bony skull tumors of extradural origin allowed
- No intradural soft tissue tumors
- Askin's tumor of the chest wall allowed
- Chest wall tumors with ipsilateral pleural effusions or ipsilateral pleural-based
secondary tumor nodules allowed
- No contralateral pleural effusions
- No metastatic disease or distant node involvement
- One pulmonary or pleural nodule greater than 1 cm in diameter OR more than 1
nodule greater than 0.5 cm in diameter are considered pulmonary metastasis
- Solitary lung nodules of 0.5-1 cm OR multiple nodules of 0.3-0.5 cm allowed
unless biopsy positive for tumor
- Light microscopic appearance (hematoxylin and eosin stained) consistent with Ewing's
sarcoma or peripheral PNET
- No immunohistochemical or ultrastructural evidence of rhabdomyosarcoma
- No esthesioneuroblastoma
- Clinically or pathologically involved regional lymph nodes allowed
- No CNS involvement
PATIENT CHARACTERISTICS:
Age:
- 50 and under at diagnosis
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Bilirubin no greater than 1.5 mg/dL
Renal:
- Creatinine normal for age
- Creatinine clearance or isotope glomerular filtration rate at least 75 mL/min
Cardiovascular:
- Shortening fraction at least 28% by echocardiography OR
- Ejection fraction at least 55% by radionuclide angiogram
Other:
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No other prior malignancy except skin cancer diagnosed at least 5 years ago and
currently in remission
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No prior immunotherapy for skin cancer
- No concurrent sargramostim (GM-CSF)
- No concurrent pegfilgrastim
Chemotherapy:
- No prior chemotherapy
Endocrine therapy:
- Not specified
Radiotherapy:
- No prior radiotherapy
Surgery:
- Prior complete or partial excision of primary tumor allowed
Ages Eligible for Study
0 Years - 50 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
ccto-office@stanford.edu
Not Recruiting